Taiwanese study tracking anaplastic thyroid cancer
Part of Cancer clinical trials.
This study collects information from people diagnosed with anaplastic thyroid cancer, a rare and aggressive form of thyroid cancer, to learn more about the disease and improve future care. If you or a loved one have this diagnosis, participating helps build a registry that can guide better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of anaplastic thyroid cancer, a rare and fast-growing type of thyroid cancer.
- Your diagnosis was made in 2015 or later.
- You are willing to allow your medical information to be collected and used for this study.
- If you are participating on behalf of someone who has passed away, they must have died before June 30, 2025.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world information from patients with advanced thyroid cancer to better understand how standard treatments and specialized procedures work. Your participation will help improve care for others with this type of cancer.
This study is comparing two different ways of giving radiation therapy for anaplastic and poorly differentiated thyroid cancer. The goal is to see which method is more effective in treating the cancer.
This study is a registry that collects information about adults with certain types of thyroid cancer. It may help researchers learn more about these cancers and how people are doing over time.
This study looks at a small blood test (called ctDNA) and tumor tissue to understand how advanced thyroid cancers change over time. It may help doctors better monitor cancer growth and guide treatment choices.
This trial tests a new treatment for anaplastic thyroid cancer that combines two immune-based therapies: NKG2D CAR-NK cells (a type of white blood cell engineered to attack cancer) and a PD-1 inhibitor (a drug that helps the immune system fight cancer). The goal is to see if this combination is safe and effective.
This trial tests a combination of two medications—zanzalintinib (a targeted drug that may stop cancer cells from growing) and cemiplimab (an immunotherapy that helps your immune system fight cancer)—for people with anaplastic thyroid cancer, a rare and aggressive type. The goal is to see if this combo helps shrink or control the cancer.
Hear when a new Thyroid Carcinoma, Anaplastic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.